Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer
Rui Han, Conghua Lu, Chen Hu, Yuanyao Dou, Jun Kang, Caiyu Lin, Di Wu, Wei-ling Jiang, Yin Guo-qing, Yong He
Topics & Concepts
OsimertinibAnaplastic lymphoma kinaseCancer researchPharmacologyTyrosine-kinase inhibitorReceptor tyrosine kinaseEpidermal growth factor receptorLung cancerChemistryMedicineKinaseCancerErlotinibInternal medicineBiochemistryMalignant pleural effusionPancreatic and Hepatic Oncology ResearchPhagocytosis and Immune RegulationLung Cancer Treatments and Mutations